Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to invest in now. On April 30, TheFly reported that JPMorgan trimmed the price target on Recursion ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...

The concept of a meme stock was born about five years ago. It refers to a publicly traded company that gains substantial market value practically overnight (sometimes literally) due to significant ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Act now: the analyst who called NVIDIA in 2010 just named ...

What's going on with Recursion? Cramer stated on Mad Money at the end of last week's trading that Recursion's stock performance has "been disastrous" since the company's management appeared on his ...

High-rolling investors have positioned themselves bullish on Recursion Pharmaceuticals (NASDAQ:RXRX), and it's important for retail traders to take note. \This activity came to our attention today ...